TNBC L1——

KEYNOTE-355：Approved in CPS≥10；【帕博利珠单抗+化疗（白蛋白紫杉醇、紫杉醇或吉西他滨）】

IMpassion 130：Approved in ≥1% PD-L1, but withdrawn in Aug 2021 after Impassion-131 failed；【Tecentriq+nab-paclitaxel】

IMpassion 131：Upsized by 11%, failed in Oct 2020；【Tecentriq®+paclitaxel】

IMpassion 132：Upsized by 63%, completion delayed from Jul 2019 to Jun 2023；【Tecentriq®+卡铂/吉西他滨或卡培他滨】

NCT04335006：Terminated (Sponsor R & D Strategy Adjustment)；【Carelizumab+nab-paclitaxel±apatinib】

TORCHLIGHT：达到终点；【特瑞普利单抗+nab-paclitaxel】

$罗氏控股(RHHBY)$ $君实生物-U(SH688180)$ $恒瑞医药(SH600276)$